

# Perlmutter Cancer Center

NYU Langone Health Presentations at ASCO  
May 30, 2026

**Session:** Women's Networking Center  
**Career Conversation Mentor:** Marc Braunstein, MD, PhD  
**Time:** 7:30-8:25AM

**Session:** Is the Juice Worth the Squeeze: Challenges in Combination Therapy for Non–Small Cell Lung Cancer  
**Title:** First-line (1L) divarasil plus pembrolizumab (pembro) in advanced or metastatic KRAS G12C+ non–small cell lung cancer (NSCLC): Results from the Krascendo-170 study  
**Co-Author:** Rajwanth Veluswamy, MD  
**Time:** 8:00-9:30AM  
**Location:** Arie Crown Theater  
**Abstract Number:** 8510

**Session:** Care Delivery/Models of Care  
**Title:** Optimization of geospatial oncologist placement: A maximum coverage problem approach  
**First Author/Presenter:** Ryan James Crowley  
**Time:** 9:00AM-12:00PM  
**Location:** Hall A - Posters and Exhibits  
**Abstract Number:** 1609

**Session:** Care Delivery/Models of Care  
**Title:** Geographic migration patterns of practicing medical oncologists in the United States, 2020-2025  
**Co-Author:** Ryan James Crowley  
**Time:** 9:00AM-12:00PM  
**Location:** Hall A - Posters and Exhibits  
**Abstract Number:** 1527

**Session:** Care Delivery/Models of Care  
**Title:** Association between physician characteristics and likelihood of caring for underserved patients with cancer  
**Co-Author:** Dowin Boatright, MD

**Time:** 5/30/2026, 9:00AM-12:00PM  
**Location:** Hall A - Posters and Exhibits  
**Abstract Number:** 1646

**Session:** Care Delivery/Models of Care  
**Title:** SMS message sentiment as a predictive indicator of quality of life and program adherence in oncology nutrition  
**Co-Author:** Stacy Loeb, MD  
**Time:** 5/30/2026, 9:00AM-12:00PM  
**Location:** Hall A - Posters and Exhibits  
**Abstract Number:** 1627

**Session:** Gastrointestinal Cancer—Colorectal and Anal  
**Title:** Antitumor activity of amivantamab by consensus molecular subtypes in RAS/BRAF wild-type metastatic colorectal cancer: Secondary analyses from the phase 1b/2 OrigAMI-1 study  
**Co-Author:** Paul Oberstein, MD  
**Time:** 9:00AM-12:00PM  
**Location:** Hall A - Posters and Exhibits  
**Abstract Number:** 3548

**Session:** Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary  
**Title:** Final results and preliminary correlative analysis of a phase I study of anetumab ravtansine in combination with checkpoint inhibitors and gemcitabine in mesothelin-positive advanced pancreatic adenocarcinoma (NCI10208)  
**Co-Author:** Paul Oberstein, MD  
**Time:** 9:00AM-12:00PM  
**Location:** Hall A - Posters and Exhibits  
**Abstract Number:** 4205

**Session:** Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary  
**Title:** Multi-cohort validation of a multi-analyte liquid biopsy test for early-stage pancreatic cancer detection  
**Co-Author:** Anirban Maitra, MD  
**Time:** 9:00AM-12:00PM  
**Location:** Hall A - Posters and Exhibits  
**Abstract Number:** 4139

**Session:** Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

**Title:** Global insights into survival outcomes and unmet therapeutic needs in KRAS-mutant gallbladder cancer: A comprehensive federated network analysis

**Presenter:** Ghulam Shah, MD

**Time:** 9:00AM-12:00PM

**Location:** Hall A - Posters and Exhibits

**Abstract Number:** 4141

**Session:** Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

**Title:** Precision Promise (PrP): Success rates of paired biopsies and biomarker testing results for metastatic pancreatic cancer (mPDAC) in a multi-center trial

**Co-Authors:** Anirban Maitra, MD, Manuel Hidalgo, MD

**Time:** 9:00AM-12:00PM

**Location:** Hall A - Posters and Exhibits

**Abstract Number:** 4196

**Session:** Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

**Title:** Extrapulmonary small cell carcinoma treated with conventional or tumor-targeted topoisomerase I inhibition plus ATR blockade: Clinical outcomes and molecular correlates.

**Co-Author:** Elaine Shum, MD

**Time:** 1:30-4:30PM

**Location:** Hall A - Posters and Exhibits

**Abstract Number:** 3027

**Session:** Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

**Title:** A phase 1a/b study of RGT-61159, an oral MYB splicing modulator, in patients with advanced adenoid cystic carcinoma and colorectal cancer

**Co-Author:** Zujun Li, MD

**Time:** 1:30-4:30PM

**Location:** Hall A - Posters and Exhibits

**Abstract Number:** 3089

**Session:** Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

**Title:** First-in-human phase 1/2 study of ETX-19477, an oral, potent, and selective PARG inhibitor, in patients with advanced solid tumors (ERADIC8)

**Co-Author:** Nancy Chan, MD

**Time:** 1:30-4:30PM

**Location:** Hall A - Posters and Exhibits

**Abstract Number:** 3109

**Session:** Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology  
**Title:** ETCTN 10302: A randomized phase II trial of radium-223 dichloride in combination with paclitaxel in patients with bone metastatic breast cancer  
**Co-Author:** Nancy Chan, MD  
**Time:** 1:30-4:30PM  
**Location:** Hall A - Posters and Exhibits  
**Abstract Number:** 3096

**Session:** Head and Neck Cancer  
**Title:** NRG-HN006: Randomized phase II/III trial of sentinel lymph node biopsy versus elective neck dissection for early-stage oral cavity cancer  
**Co-Author:** Cheng Z. Liu, MD, PhD  
**Time:** 1:30-4:30PM  
**Location:** Hall A - Posters and Exhibits  
**Abstract Number:** TPS6138

**Session:** Developmental Therapeutics—Immunotherapy  
**Title:** Phase 1A/B study of AB248, a CD8+ selective IL-2 mutein fusion protein, alone or in combination with pembrolizumab, in patients with advanced solid tumor malignancies.  
**Co-Author:** Janice Mehnert, MD  
**Time:** 1:30-4:30PM  
**Location:** Hall A - Posters and Exhibits  
**Abstract Number:** 2616

**Session:** Developmental Therapeutics—Immunotherapy  
**Title:** A logic-gated chimeric antigen receptor T-cell (CAR T) therapy with an armored, membrane-tethered IL-12 booster in patients with advanced solid tumors with HLA-A\*02 loss of heterozygosity (LOH): EVEREST-2, a phase 1/2 study  
**First Author/Presenter:** Salman Punekar, MD  
**Time:** 1:30-4:30PM  
**Location:** Hall A - Posters and Exhibits  
**Abstract Number:** TPS2673

**Session:** Symptom Science and Palliative Care  
**Title:** Organ-specific proteomic aging clocks (PACs) and mortality in cancer survivors  
**Co-Author:** Aditya Surapaneni, PhD  
**Time:** 1:30-4:30PM  
**Location:** Hall A - Posters and Exhibits  
**Abstract Number:** 12112

**Title:** Roundtable with Program Directors: Application & Interview Success Strategies

**Participant:** Marc Braunstein, MD, PhD

**Time:** 2:00-2:45PM

**Location:** Hall C, Trainee & Early Career Lounge

**Session:** Lung Cancer—Non-Small Cell Metastatic

**Title:** DZD6008, a fourth-generation EGFR TKI in pretreated NSCLC patients with EGFR C797X mutations: Results from phase 1/2 studies.

**Co-Author:** Elaine Shum, MD

**Time:** 2:27-2:33PM

**Location:** Hall D2

**Abstract Number:** 8520

**Session:** Genitourinary Cancer—Prostate, Testicular, and Penile

**Title:** A phase 2 trial of androgen deprivation therapy interruption in patients responding exceptionally to androgen receptor pathway inhibitor in metastatic hormone-sensitive prostate cancer (A-DREAM / Alliance A032101)

**Co-Author:** Andrew L. Laccetti, MD

**Time:** 4:12-4:24PM

**Location:** Hall D1

**Abstract Number:** 5004

**Session:** Melanoma/Skin Cancers

**Title:** MATRiX: A randomized phase II trial of tuvusertib (ATR inhibitor) with or without avelumab in advanced anti-PD(L)-1 refractory Merkel cell carcinoma

**Co-Author:** Maya Dimitrova, MD

**Time:** 4:42-4:48PM

**Location:** E451

**Abstract Number:** LBA9514